Curi Bio is accelerating the discovery of the next generation of medicines by integrating human cells, systems, and data.
Location: United States
Employees: 11-50
Phone: +1 800-913-4403
Total raised: $26M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | UTC Invest... | utc.co.kr |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.12.2025 | Series B | $10M | - |
| 03.01.2022 | Series A | $10M | - |
| 18.03.2021 | Series A | $6M | - |
Mentions in press and media 18
| Date | Title | Description |
| 04.12.2025 | Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms | Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant preclinical discovery platform. The investme... |
| 03.12.2025 | Curi Bio Raises $10M in Series B Funding | Curi Bio, a Seattle, WA-based company delivering human-relevant functional data for drug discovery and development, raised $10M in Series B funding. The round was led by DreamCIS. The company intends to use the funds to accelerate the devel... |
| 08.04.2025 | Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle | We are thrilled to share that our portfolio company, Curi Bio has officially opened its new global headquarters in Seattle. This state-of-the-art facility enhances their capabilities to advance human-relevant drug discovery and development.... |
| 15.02.2023 | Tech Moves: T-Mobile tech leader to retire; Curi Bio and CrowdCow appoint CEOs; and more | Elizabeth Liu. (Crowd Cow Photo) — Joe Heitzeberg is stepping down as CEO of CrowdCow, the Seattle-based meat and seafood marketplace he co-founded in 2015. Elizabeth Liu, the company’s vice president of marketing, will take on the role. Li... |
| 02.06.2022 | A Scalable System to Engineer Human 3D Muscle Tissues for Drug Discovery, Upcoming Webinar Hosted by Xtalks | Guest speaker Dr. Chris Hinckley from Biogen, will present some of Biogen’s recent data generated using the 3D modelling platform. TORONTO (PRWEB) June 02, 2022 3D cellular models and organs-on-chips are poised to add tremendous value to tr... |
| 03.01.2022 | Curi Bio scores $10M for stem cell-focused drug discovery platform | Photo: Longhua Liao/Getty Images |
| 03.01.2022 | Curi Bio lands $10M Series A | Curi Bio has raised $10 million from investors including Dynamk Capital and DS Asset Management. Based in Seattle, the company is a creator of human stem cell-based products designed to aid the development of genetic medicines and cell ther... |
| 03.01.2022 | Curi Bio Closes $10M Series A Funding Round | Curi Bio Inc., a Seattle, WA-based developer of human stem cell-based platforms for drug discovery, held the second closing of a $10m Series A financing. New investors UTC Investment and DS Asset Management joined current investor and Serie... |
| 30.12.2021 | Curi Bio Closes $10M Oversubscribed Series A | SEATTLE, WA, Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, has announced the second closing of a $10 million oversubscribed Series A financing. >> Click here for more funding data on Curi Bio ... |
| 29.12.2021 | Curi Bio Closes $10M Series A in Oversubscribed Round | Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced today the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, j... |
Show more